{
    "clinical_study": {
        "@rank": "115815", 
        "arm_group": [
            {
                "arm_group_label": "Intermediate embolization", 
                "arm_group_type": "Experimental", 
                "description": "TACE with substatsis using gelfoam"
            }, 
            {
                "arm_group_label": "Complete embolization", 
                "arm_group_type": "Active Comparator", 
                "description": "TACE with complete embolization using gelfoam"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study was to evaluate whether survival of patients who underwent TACE with\n      unresectable HCC can benefit from intermediate-levels of embolization."
        }, 
        "brief_title": "Survival According to the Feeding Artery Obliteration by Chemoembolization for Unresectable Hepatocellular Carcinoma", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hepatocellular Carcinoma", 
            "Transarterial Chemoembolization"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjective angiographic chemoembolization endpoints (SACE) levels were developed to\n      standardize the embolic endpoints of transarterial chemoembolization (TACE) for\n      hepatocellular carcinoma (HCC). It determined the antegrade arterial flow and residual tumor\n      blush as follows: I, normal-normal; II, reduced-reduced; III, reduced-none; IV, none-none.\n      SACE level II and III indicates intermediate-levels of embolization, whereas IV indicates\n      overembolization. The aim of this study was to evaluate whether survival of patients who\n      underwent TACE with unresectable HCC can benefit from intermediate-levels of embolization."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age over 18\n\n          -  ECOG performance status 0-2\n\n          -  Hepatocellular carcinoma diagnosed histologically or clinically\n\n          -  Tumor numbers of 5 or less\n\n          -  No history of treatment for hepatocellular carcinoma\n\n          -  Patients with informed consent\n\n        Exclusion Criteria:\n\n          -  Extrahepatic metastasis\n\n          -  Rupture of hepatocellular carcinoma\n\n          -  Infiltrative hepatocellular carcinoma\n\n          -  Malignancy other than hepatocellular carcinoma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677468", 
            "org_study_id": "2011-12-122"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intermediate embolization", 
                "description": "TACE with substasis using gelfoam", 
                "intervention_name": "Intermediate embolization", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "Adriamycin", 
                    "Cysplatin", 
                    "Gelfoam"
                ]
            }, 
            {
                "arm_group_label": "Complete embolization", 
                "description": "TACE with complete embolization using gelfoam", 
                "intervention_name": "Complete embolization", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "Adriamycin", 
                    "Cysplatin", 
                    "Gelfoam"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxorubicin", 
                "Gelatin Sponge, Absorbable"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatocellular carcinoma", 
            "Transarterial chemoembolization"
        ], 
        "lastchanged_date": "August 29, 2012", 
        "location": [
            {
                "contact": {
                    "email": "ckp@hallym.or.kr", 
                    "last_name": "Choong Kee Park, M.D., Ph.D.", 
                    "phone": "82-31-380-3708"
                }, 
                "facility": {
                    "address": {
                        "city": "Anyang", 
                        "country": "Korea, Republic of", 
                        "zip": "431070"
                    }, 
                    "name": "Hallym Sacred Heart Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "djkim@hallym.ac.kr", 
                    "last_name": "Dong Joon Kim, M.D., Ph.D.", 
                    "phone": "82-33-741-1226"
                }, 
                "facility": {
                    "address": {
                        "city": "Chuncheon", 
                        "country": "Korea, Republic of", 
                        "zip": "200060"
                    }, 
                    "name": "Chuncheon Sacred Heart Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dr.sanghoon.park@gmail.com", 
                    "last_name": "Sang Hoon Park, M.D., Ph.D.", 
                    "phone": "82-2-829-5493"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "150950"
                    }, 
                    "name": "Kangnam Sacred Heart Hostpita"
                }, 
                "investigator": {
                    "last_name": "Sang Hoon Park, M.D., Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase Study About Feeding Artery Obliteration by Chemoembolization on Survival of Patients With Unresectable Hepatocellular Carcinoma", 
        "overall_contact": {
            "email": "dr.sanghoon.park@gmail.com", 
            "last_name": "Sang Hoon Park, M.D., Ph.D.", 
            "phone": "82-2-829-5493"
        }, 
        "overall_contact_backup": {
            "email": "dr.goforit@gmail.com", 
            "last_name": "Su Rin Shin, M.D.", 
            "phone": "82-2-829-5490"
        }, 
        "overall_official": {
            "affiliation": "Hallym University Medical Center", 
            "last_name": "Sang Hoon Park, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Survival rate of the subjects 6 months after TACE", 
                "measure": "Survival rate of the subjects", 
                "safety_issue": "No", 
                "time_frame": "6 months after TACE"
            }, 
            {
                "description": "Survival rate of the subjects, 12 months after TACE", 
                "measure": "Survival rate of the subjects", 
                "safety_issue": "Yes", 
                "time_frame": "12 months after TACE"
            }, 
            {
                "description": "Survival rate of the subjects, 18 months after  TACE", 
                "measure": "Survival rate of the subjects", 
                "safety_issue": "Yes", 
                "time_frame": "18 months after  TACE"
            }, 
            {
                "description": "Survival rate of the subjects, 24 months after  TACE", 
                "measure": "Survival rate of the subjects", 
                "safety_issue": "Yes", 
                "time_frame": "24 months after  TACE"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677468"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Disease free survival of the subjects, 24 months after TACE", 
                "measure": "Disease free survival of the subjects", 
                "safety_issue": "No", 
                "time_frame": "6, 12, 18, and 24 months after TACE"
            }, 
            {
                "description": "The incidence of infection, hemorrhage, 24 months after TACE", 
                "measure": "Complication rate of TACE", 
                "safety_issue": "Yes", 
                "time_frame": "6, 12, 18, and 24 months after TACE"
            }
        ], 
        "source": "Hallym University Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hallym University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}